Full Archive

Let the games begin!

Now that all the major diabetes tech companies have reported it’s safe to say two things. 1. Ozempic is NOT killing diabetes tech. 2. Consolidation is next on the agenda. It’s the second point that needs to examined further. As we noted last week Tandem most likely will be the catalyst for the coming consolidation. With a market cap of just over $1 Billion, sitting on almost $500 million in cash and an...

TGIF

As we head into the weekend, I’ve been trying to come up with new superlatives to describe how Lilly and Novo Nordisk are doing. To say their results were spectacular is an understatement but also not at all surprising. These two longtime rivals are just killing it, and this is just the beginning. Think of where sales will be when they fix their manufacturing issues and reimbursement improves. Not to...

Is this the same market?

Before I get into the earnings released by Insulet this afternoon here’s something to chew on. Tandem closed at $15.20 down another 14.37%. As it stands today this company with almost $500 million in cash and some 440,000 users has a market cap of …. Wait for it … $988 MILLION – think about that just for a moment boys and girls. And as you are about to see it’s...

This is NOT going to end well.

Looking over the results released by Tandem yesterday and reading through the earnings call transcript a few things stood out- 1. Tandem is almost like a teenager who gets caught in lie and then comes up with multiple explanations to explain away this lie. 2. The company is also trying to jump on the GLP-1 bandwagon and using clinical data to back up their assertion that increasing GLP-1 usage will help Tandem...

This is the way

It really isn’t enough to say once again we were spot on, and analysts were dead wrong. Momma Kliff didn’t like it when any of her children gloated preferring instead that our accomplishments stand on their own merit. Mom always said when you do a good job people will notice, when others screw up, they’ll notice that more and appreciate you more. Well, there is no question the analysts screwed...

The Floodgates are set to open.

Today we learned that Dexcom was among the investors in a Series B funding round for diabetes/obesity startup Signos. The Friday before Ilant Health a “new virtual provider targeting obesity treatment” launched with $3 million in funding. I’m pretty sure there are more that we missed but this is just the beginning. Get ready for investor money to start pouring into what we are calling the Ozempic Cost Containment (OCC)...

Exhibit One

Mark Twain once stated that reports of his demise have been greatly exaggerated. The same can be said for how sales of Ozempic and all the other GLP-1’s would impact sales of diabetes tech. We got our first set of facts toady when Abbott reported strong growth for sales of Libre. This really should not come as a surprise as once again we were right, and the analysts were wrong. We’ll...

WordPress PopUp Plugin